Last reviewed · How we verify
NCT05462158
Message Testing for CKD
NA trial testing Impact of Nudges on CKD Testing in Available for Members Text Message in 8,637 participants. Completed in 15 December 2022.
15 September 2022
Quick facts
| Lead sponsor | University of Pennsylvania |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 8,637 |
| Start date | 15 March 2022 |
| Primary completion | 15 September 2022 |
| Estimated completion | 15 December 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Impact of Nudges on CKD Testing
Conditions studied
- Available for Members Text Message — all drugs for Available for Members Text Message →
- Checked Health Text Message — all drugs for Checked Health Text Message →
- No Text Message — all drugs for No Text Message →
Sponsor
University of Pennsylvania
Who can join
Eligibility, any sex, with Available for Members Text Message or Checked Health Text Message. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Members of CVS/Aetna will receive one of two text messages or receive no text message at all. In the available for members condition, participants will receive a text message that says, "Two common kidney tests have been made available for members. By taking them, you could stay ahead of any problems and keep enjoying life. Schedule a doctor visit today to ask about them." In the Checked Health condition, the message will say, "Have you checked your kidney health recently? By taking two common kidney tests, members can stay ahead of any problems and keep enjoying life. Schedule a doctor visit today to ask about them." There will also be a group of members that do not receive a text message at all.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05462158
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of Pennsylvania trials
Trials by the same sponsor.
- NCT06081153 — Mechanistic Clinical Trial of PCSK9 Inhibition for AAA · EARLY_PHASE1 · not yet recruiting
- NCT07415772 — Effect of cTBS on Startle and TMS-evoked BOLD · NA · not yet recruiting
- NCT07489430 — DaxibotulinumtoxinA for Blepharospasm · Phase 2 · not yet recruiting
- NCT07463131 — Negative Income Tax Trial · NA · not yet recruiting
- NCT06645769 — Na-Phenylbutyrate VAscular Trial · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05462158 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Pennsylvania
- Last refreshed: 13 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05462158.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing